Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial

Atogepant is a selective oral calcitonin gene‐related peptide receptor antagonist in development for migraine prevention. Here, we report the pharmacokinetics (PK) and safety of single‐dose 60 mg atogepant in participants with severe, moderate, or mild hepatic impairment and matched participants wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Boinpally, Ramesh, Jakate, Abhijeet, Butler, Matthew, Borbridge, Lisa, Periclou, Antonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359408/
https://www.ncbi.nlm.nih.gov/pubmed/33501783
http://dx.doi.org/10.1002/cpdd.916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359408/
https://www.ncbi.nlm.nih.gov/pubmed/33501783
http://dx.doi.org/10.1002/cpdd.916

Ejemplares similares